Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates

Core Insights - Agios Pharmaceuticals reported a quarterly loss of $1.78 per share, better than the Zacks Consensus Estimate of a loss of $1.93, representing an earnings surprise of +7.77% [1] - The company generated revenues of $12.88 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 27.69% and up from $8.96 million a year ago [2] - Agios Pharmaceuticals shares have increased by approximately 27.7% year-to-date, outperforming the S&P 500's gain of 17.2% [3] Financial Performance - Over the last four quarters, Agios Pharmaceuticals has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$2.04 on revenues of $10.91 million, and for the current fiscal year, it is -$7.47 on revenues of $42.13 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Agios Pharmaceuticals belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment [5]